If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,983.00    -32.00 (-1.59%)
Bid:
1,982.50
Ask:
1,983.50
Spread: 1.00 (0.05%)
Market Cap: £79.43b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

GSK publishes Annual Report 2022

10 Mar 2023 10:36

RNS Number : 5978S
GSK PLC
10 March 2023
 

 

GSK plc

(the 'Company')

 

Publication of Annual Report 2022

 

 

The Company has today published on its website www.annualreport.gsk.com its Annual Report for the year ended 31 December 2022 ('Annual Report 2022').

 

In compliance with Listing Rule 9.6.1R of the UK Financial Conduct Authority ('FCA'), the Annual Report 2022 has been submitted to the FCA's National Storage Mechanism ('NSM') and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

A hard copy version of the Annual Report 2022 and the Notice of Annual General Meeting 2023 ('AGM Notice') will be sent to those shareholders who have elected to receive paper communications on or around 27 March 2023. The AGM Notice will be made available to shareholders who have not elected to receive paper communications on the same date.

 

This announcement is not a substitute for reading the Annual Report 2022 in full.

 

Additional Information

 

For the purposes of complying with the FCA's Disclosure and Transparency Rules ('DTRs') and the requirements imposed on issuers through the DTRs, information required to be communicated with the media in unedited full text was included in the Annual Report 2022. The Annual Report 2022 was submitted to the NSM and will shortly be available for inspection. It is also available on the Company's website as noted above.

 

This announcement is made in accordance with DTR 6.3.5R(1A).

 

V A Whyte

Company Secretary

 

10 March 2023

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSEAEDEFDSDEFA
Date   Source Headline
1st Jul 20263:00 pmRNSTotal Voting Rights
29th Jun 20263:00 pmRNSTransaction in Own Shares
29th Jun 20263:00 pmRNSHolding(s) in Company
26th Jun 20263:00 pmRNSHolding(s) in Company
24th Jun 20263:30 pmRNSDirector/PDMR Shareholding
24th Jun 20262:52 pmRNSGSK announces tender offer to acquire Nuvalent
23rd Jun 20263:30 pmRNSDirector/PDMR Shareholding
22nd Jun 20263:00 pmRNSTransaction in Own Shares
17th Jun 20264:06 pmRNScUTI oral antibiotic Tebipenem approved by US FDA
15th Jun 20263:00 pmRNSTransaction in Own Shares
12th Jun 20267:00 amRNSMomelotinib orphan drug designations for VEXAS
11th Jun 20263:30 pmRNSDirector/PDMR Shareholding
10th Jun 20263:30 pmRNSDirector/PDMR Shareholding
9th Jun 20265:51 pmRNSDr Hal Barron – New Directorship
9th Jun 20267:00 amRNSGSK enters agreement to acquire Nuvalent, Inc.
8th Jun 20263:00 pmRNSTransaction in Own Shares
1st Jun 20263:00 pmRNSTotal Voting Rights
1st Jun 20263:00 pmRNSTransaction in Own Shares
28th May 20269:30 amRNSPositive Phase 3 data for bepirovirsen
27th May 20263:30 pmRNSDirector/PDMR Shareholding
26th May 20263:00 pmRNSAdmission to Trading
26th May 20263:00 pmRNSTransaction in Own Shares
22nd May 202610:30 amRNSQ2 2026 Results Date Confirmed - 28 July 2026
20th May 20263:30 pmRNSDirector/PDMR Shareholding
19th May 20263:30 pmRNSDirector/PDMR Shareholding
18th May 20263:00 pmRNSTransaction in Own Shares
18th May 20267:00 amRNSJapan MHLW approves Arexvy for adults 18-49 AIR
14th May 20263:30 pmRNSDirector/PDMR Shareholding
11th May 20263:30 pmRNSDirector/PDMR Shareholding
11th May 20267:05 amRNSCollaboration with CTTQ for bepirovirsen
11th May 20267:00 amRNSGSK - final tranche of share buyback programme
6th May 20266:22 pmRNSResult of AGM
5th May 20263:30 pmRNSDirector/PDMR Shareholding
1st May 20263:00 pmRNSHolding(s) in Company
1st May 20263:00 pmRNSTotal Voting Rights
29th Apr 20263:30 pmRNSDirector/PDMR Shareholding
29th Apr 20267:00 amRNS1st Quarter Results
28th Apr 20263:30 pmRNSDirector/PDMR Shareholding
28th Apr 20267:00 amRNSBepirovirsen priority review US filing acceptance
27th Apr 202612:00 pmRNSEfimosfermin granted US/EU regulatory designations
27th Apr 20267:00 amRNSTESARO update on AnaptysBio Inc. litigation
24th Apr 20263:30 pmRNSDirector/PDMR Shareholding
23rd Apr 20267:00 amRNSTransaction in Own Shares
22nd Apr 20267:00 amRNSTransaction in Own Shares
21st Apr 20267:00 amRNSTransaction in Own Shares
20th Apr 20263:30 pmRNSDirector/PDMR Shareholding
20th Apr 20267:00 amRNSBlenrep approved in China for 2L+ multiple myeloma
20th Apr 20267:00 amRNSTransaction in Own Shares
17th Apr 20267:00 amRNSTransaction in Own Shares
16th Apr 20263:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.